Thursday, July 17, 2008
By 2020 the Pharma R&D process may be shortened by two-third, success rates may dramatically increase, and clinical trial costs could be cut substantially, according to a research report by PricewaterhouseCoopers, entitled Pharma 2020: Virtual R&D, which path will you take? New computer-based technologies will create a greater understanding of disease biology and lead to the evolution of 'virtual man' to enable researchers to predict the effects of new drug candidates before they enter trials with human beings, notes the study.
During this week's GEN podcast, Dr. Neil Patel explains why the pharmaceutical industry is at a pivotal point in its development. He talks about seven key trends that are reshaping the pharmaceutical marketplace and posing a challenge to business. Dr. Patel describes the current pharma research process and addresses what it might look like once robust computer models of the entire human body are available. He also discusses the nature of the changes emerging in technology and the business environment that will provide the pharma industry with new strategies to compete successfully in the future and on a global basis.
7/18/2008
It appears to create the virtual R&D is to create the “virtual man”. Patents, health policies, regulations will be reshaped or affected as the “Virtual Man” reacts to every known medication or chemical or molecule or situation applied to it. One interesting thing to see is how binding will be the results from any research involving the “virtual man” globally. Certainly a collaborative effort among developing nations towards its creation may be a practical path in producing affordable medicines for their population.
Natural health products companies will likewise be benefited because it will help in meeting their regulatory requirement for clinical trials. The dynamics involved would certainly be worth watching.
7/19/2008
Computer modeling that help to understand the biological interactions between circuits involved in the disease, are very helpful because many chronic diseases are due to an imbalance of a system rather than to the deficiency of one or a few specific targets. Companies like Entelos in the metabolism and inflammation area; Optimata in the oncology field; In Silico Biosciences in CNS diseases build mechanistic mathematical models based upon the integration of many published data on animal studies, but also integrating many human clinical data. In that way their hybrid models are real translational tools to overcome the limitations of animal models in drug discovery and development and to improve the predictability of preclinical drug results.
NOTICE: As such, the comments on this blog were, are, and will always be solely the opinions of the individuals leaving them. In no way does Genetic Engineering & Biotechnology News, GEN Publishing, Inc., or Mary Ann Liebert ,Inc. endorse, condone, agree with, sponsor, etc. these comments.
ADVERTISEMENT
INTERVIEW:
(BIO) BANKING IN LUXEMBOURG - Interview with Robert Hewitt, Ph.D., CEO, Integrated Biobank of Luxembourg, and European Editor, Biopreservation and Biobanking (published by Mary Ann Liebert, Inc.)
...MORE
NewsArticles Blogs| Most Viewed | Most Emailed | Top Searches |
|---|---|---|
| Unclog the Innovation Bottleneck at our Nation’s Universities | ||
| (Bio) Banking in Luxembourg | ||
ADVERTISEMENT
Subscribe to RSS
HOME
Hot Topics
All Topics
Archived
Post a Topic
RSS
LISTEN
COMMENT
Email
Print
Back
Share
Save